# Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

> **NCT00149292** · PHASE2 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 195 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LY2140023
- **DRUG:** olanzapine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00149292
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-23
- **Primary completion:** 2006-07-17
- **Final completion:** 2006-07-17
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149292, "Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00149292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*